Warren Abel, MD
Critical Care Medicine · St Petersburg, FLNPI 1912939067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 395 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,278, 2.5 times the $898 reported in 2019. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Boehringer Ingelheim$692
- Actelion Pharmaceuticals US, Inc.$689
- Insmed, Inc.$560
- Regeneron Healthcare Solutions, Inc.$434
- plus $4K from 42 others
Across 36 payments — averaging $12,182 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$180K
- E.r. Squibb & Sons, L.L.C.$156K
- Sanofi US Services Inc.$63K
- GSK$29K
- Boehringer Ingelheim$6K
- Astrazeneca UK Limited$5K
What the payments were for
- Food & beverage$8,91499%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MONARCH$134
- AIRSUPRA$130
- UPTRAVI$122
- Da Vinci Surgical System$112
How this compares
$8,977 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $210,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 125 | $144,070 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $76,059 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $56,098 |
| Ambrisentan | 23 | $46,114 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $27,301 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $24,191 |
| Spiriva RespimatTiotropium Bromide | 16 | $23,532 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $20,085 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $12,904 |
| Spiriva HandihalerTiotropium Bromide | 15 | $12,029 |
| Sildenafil Citrate | 11 | $11,017 |
| BreynaBudesonide/Formoterol Fumarate | 31 | $10,939 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 158 | $5,418 |
| Ventolin HfaAlbuterol Sulfate | 46 | $4,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $692 | $258,29462 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,347 | $227,470228 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,127 | $96,145119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in St Petersburg
- Vinny SamuelSt Petersburg$171K
- Ala AhmadSt Petersburg$62K
- Hudman HooSt Petersburg$51K
- Eric SchillingSt Petersburg$14K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
- Omid ZadOrlando$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.